BUSINESS

Kobayashi Kako Ditches Turnaround Plan with Manufacturing Transfer to Sawai

December 7, 2021
Embattled generic maker Kobayashi Kako has given up on rebuilding itself from a high-profile GMP scandal that has rattled the industry since late last year, with a decision to transfer its manufacturing facilities and staffers to Big 3 player Sawai…

To read the full story

Related Article

BUSINESS

By Yoshinori Sagehashi

“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…

By Philip Carrigan

Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…

Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…